Interpersonal Influences on the Choice to Treat Nausea during Pregnancy with Medication or Cannabis

Amanda H. Mercer; Katherine E. MacDuffie; Elliott M. Weiss; Allegra Johnson; Stephen R. Dager; Natalia Kleinhans

doi:10.1055/a-2183-9013

American Journal of Perinatology, Table of Contents

Am J Perinatol 2024; 41(S 01): e2941-e2951
DOI: 10.1055/a-2183-9013

Original Article

Interpersonal Influences on the Choice to Treat Nausea during Pregnancy with Medication or Cannabis

Amanda H. Mercer

¹Counselor Education Department, Portland State University, Portland, Oregon

,

Katherine E. MacDuffie

²Department of Pediatrics, Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research Institute, University of Washington, Seattle, Washington

,

Elliott M. Weiss

²Department of Pediatrics, Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research Institute, University of Washington, Seattle, Washington

,

Allegra Johnson

³Department of Radiology, University of Washington, Seattle, Washington

,

Stephen R. Dager

³Department of Radiology, University of Washington, Seattle, Washington

,

Natalia Kleinhans

³Department of Radiology, University of Washington, Seattle, Washington

› Author Affiliations

Abstract

Objective This study aimed to better understand the interpersonal influences on a pregnant individual's decision of how to treat nausea and vomiting during pregnancy using a qualitative approach.

Study Design A semistructured interview guide was developed to assess pregnancy symptoms, decision-making regarding treating nausea, and interpersonal influences on treatment decisions. Interviews were conducted with 17 individuals enrolled in a neuroimaging and behavioral study of prenatal exposure to cannabis who used medication and/or cannabis to treat symptoms associated with pregnancy.

Results Interviews revealed four groups of stakeholders who influenced participant decision-making: medical providers, partners, family, and friends. Influence was categorized as either positive, negative, neutral, or absent (if not discussed or participant chose not to disclose). Those in the medication group reported only positive or neutral feedback from friends, family, partners, and providers. In contrast, the cannabis group participants reported positive feedback from friends, mixed feedback from family and partners, and negative feedback from providers, which was often felt to be stigmatizing. Many in the cannabis group also reported varying feedback from different medical providers. While the cannabis group frequently reported eliciting feedback from friends, family, and partners, the medication group often did not.

Conclusion Medication group participants reported entirely positive feedback from providers and often did not mention any feedback at all from partners, family, and friends. Cannabis group participants reported much more varied feedback, both positive and negative, from a variety of interpersonal contacts and sometimes decided to conceal their treatment choice after receiving or fearing negative feedback. We recommend further research into the health outcomes of pregnant patients who chose not to discuss their treatment decisions with providers, family, partners, or friends. We also suggest further study of possible reasons behind a lack of disclosure, including fear of stigma and/or legal consequences.

Key Points

Providers, partners, family, friends gave feedback.
Medication group got positive feedback.
Cannabis group stigmatized by providers.
Cannabis group got mixed feedback.

Keywords

marijuana - cannabis - antinausea medication - pregnancy - nausea

Full Text

References

References
1 Baggley A, Navioz Y, Maltepe C, Koren G, Einarson A. Determinants of women's decision making on whether to treat nausea and vomiting of pregnancy pharmacologically. J Midwifery Womens Health 2004; 49 (04) 350-354
2 Ayyavoo A, Derraik JGB, Hofman PL, Cutfield WS. Hyperemesis gravidarum and long-term health of the offspring. Am J Obstet Gynecol 2014; 210 (06) 521-525
3 Figueroa Gray M, Hsu C, Kiel L, Dublin S. Getting through the day: a pilot qualitative study of U.S. women's experiences making decisions about anti-nausea medication during pregnancy. BMC Pregnancy Childbirth 2018; 18 (01) 475
4 Bayrampour H, Zahradnik M, Lisonkova S, Janssen P. Women's perspectives about cannabis use during pregnancy and the postpartum period: an integrative review. Prev Med 2019; 119: 17-23
5 Greyson D, Roosevelt L, Boyd CJ. Desistance, self-treatment, or substitution: decisions about cannabis use during pregnancy. J Midwifery Womens Health 2021; 66 (01) 96-100
6 Brown QL, Sarvet AL, Shmulewitz D, Martins SS, Wall MM, Hasin DS. Trends in marijuana use among pregnant and nonpregnant reproductive-aged women, 2002–2014. JAMA 2017; 317 (02) 207-209
7 Sood S, Trasande L, Mehta-Lee SS, Brubaker SG, Ghassabian A, Jacobson MH. Maternal cannabis use in the perinatal period: data from the pregnancy risk assessment monitoring system marijuana supplement, 2016–2018. J Addict Med 2022; 16 (04) e225-e233
8 Roberson EK, Patrick WK, Hurwitz EL. Marijuana use and maternal experiences of severe nausea during pregnancy in Hawai'i. Hawaii J Med Public Health 2014; 73 (09) 283-287
9 Metz TD, Allshouse AA, McMillin GA, Silver RM, Jarlenski MP. Association of marijuana use with nausea and vomiting of pregnancy. Am J Obstet Gynecol 2022; 226 (01) S22-S23
10 Young-Wolff KC, Tucker LY, Alexeeff S. et al. Trends in self-reported and biochemically tested marijuana use among pregnant females in California from 2009–2016. JAMA 2017; 318 (24) 2490-2491
11 Howard DS, Dhanraj D, Devaiah G, Lambers D. Marijuana use in pregnancy and its effects on birth weight and gestational age at delivery [17R]. Obstet Gynecol 2017; 129 (05) 187S
12 Lynch MM, Squiers LB, Kosa KM. et al. Making decisions about medication use during pregnancy: implications for communication strategies. Matern Child Health J 2018; 22 (01) 92-100
13 Pinfold V, Dare C, Hamilton S. et al. Anti-psychotic medication decision making during pregnancy: a co-produced research study. Ment Health Rev (Brighton) 2019; 24 (02) 69-84
14 Talabi MB, Eudy AM, Jayasundara M. et al. Tough choices: exploring medication decision-making during pregnancy and lactation among women with inflammatory arthritis. ACR Open Rheumatol 2021; 3 (07) 475-483
15 Findley A, Smith DM, Hesketh K, Keyworth C. Exploring womens' experiences and decision making about physical activity during pregnancy and following birth: a qualitative study. BMC Pregnancy Childbirth 2020; 20 (01) 54
16 Boehnke KF, Scott JR, Litinas E. et al. Cannabis use preferences and decision-making among a cross-sectional cohort of medical cannabis patients with chronic pain. J Pain 2019; 20 (11) 1362-1372
17 Bottorff JL, Bissell LJL, Balneaves LG, Oliffe JL, Capler NR, Buxton J. Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study. Harm Reduct J 2013; 10: 2
18 Page SA, Verhoef MJ. Medicinal marijuana use: experiences of people with multiple sclerosis. Can Fam Physician 2006; 52 (01) 64-65
19 Satterlund TD, Lee JP, Moore RS. Stigma among California's medical marijuana patients. J Psychoactive Drugs 2015; 47 (01) 10-17
20 Tofthagen C, Perlman A, Advani P. et al. Medical marijuana use for cancer-related symptoms among Floridians: a descriptive study. J Palliat Med 2022; 25 (10) 1563-1570
21 McKenzie LB, Keim SA, Klebanoff MA. Risk perceptions about cannabis use and receipt of health-related information during pregnancy. Am J Health Promot 2022; 36 (08) 1316-1325
22 Holland CL, Nkumsah MA, Morrison P. et al. “Anything above marijuana takes priority”: obstetric providers' attitudes and counseling strategies regarding perinatal marijuana use. Patient Educ Couns 2016; 99 (09) 1446-1451
23 Mark K, Terplan M. Cannabis and pregnancy: maternal child health implications during a period of drug policy liberalization. Prev Med 2017; 104: 46-49
24 Geraghty S, Doleman G, De Leo A. Midwives' attitudes towards pregnant women using substances: informing a care pathway. Women Birth 2019; 32 (04) e477-e482
25 Marijuana use during pregnancy and lactation. The American College of Obstetricians and Gynecologists; . October 2017. Accessed July 13, 2023 at: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/10/marijuana-use-during-pregnancy-and-lactation
26 Saldana: The Coding Manual for Qualitative Researchers/Saldana, Johnny. London: SAGE Publications Ltd; 2021
27 Dedoose [Computer Software]. Los Angeles, CA: SocioCultural Research Consultants, LLC; 2021
28 Schrager NL, Adrien N, Werler MM, Parker SE, Van Bennekom C, Mitchell AA. National Birth Defects Prevention Study. Trends in first-trimester nausea and vomiting of pregnancy and use of select treatments: findings from the National Birth Defects Prevention Study. Paediatr Perinat Epidemiol 2021; 35 (01) 57-64
29 Holland CL, Rubio D, Rodriguez KL. et al. Obstetric health care providers' counseling responses to pregnant patient disclosures of marijuana use. Obstet Gynecol 2016; 127 (04) 681-687
30 Syvertsen JL, Toneff H, Howard H, Spadola C, Madden D, Clapp J. Conceptualizing stigma in contexts of pregnancy and opioid misuse: a qualitative study with women and healthcare providers in Ohio. Drug Alcohol Depend 2021; 222: 108677
31 Vanstone M, Panday J, Popoola A. et al. Pregnant people's perspectives on cannabis use during pregnancy: a systematic review and integrative mixed-methods research synthesis. J Midwifery Womens Health 2022; 67 (03) 354-372
32 Young-Wolff KC, Foti TR, Green A. et al. Perceptions about cannabis following legalization among pregnant individuals with prenatal cannabis use in California. JAMA Netw Open 2022; 5 (12) e2246912
33 Substance use during pregnancy. Guttmacher Institute; . July 1, 2023. Accessed July 13, 2023 at: https://www.guttmacher.org/state-policy/explore/substance-use-during-pregnancy
34 Ryan P, McGarry K. ‘I miss being honest’: sex workers' accounts of silence and disclosure with health care providers in Ireland. Cult Health Sex 2022; 24 (05) 688-701
35 Lerman SF, Shahar G, Czarkowski KA. et al. Predictors of satisfaction with obstetric care in high-risk pregnancy: the importance of patient–provider relationship. J Clin Psychol Med Settings 2007; 14 (04) 330-334